These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Reanalyzing reverse payment settlements: a solution to the patentee's dilemma. Wang Z Cornell Law Rev; 2014 Jul; 99(5):1227-58. PubMed ID: 25112001 [No Abstract] [Full Text] [Related]
6. An Incomplete Prescription: President Trump's Plan to Address High Drug Prices. Sarpatwari A; Avorn J; Kesselheim AS JAMA; 2018 Jun; 319(23):2373-2374. PubMed ID: 29800027 [No Abstract] [Full Text] [Related]
7. Pharmaceuticals and medical devices: business practices. Issue brief. Steiner DJ Issue Brief Health Policy Track Serv; 2012 Dec; ():1-36. PubMed ID: 23297448 [No Abstract] [Full Text] [Related]
8. Lowering the cost of prescription drugs. Jindal B J La State Med Soc; 2003; 155(1):51. PubMed ID: 12656276 [No Abstract] [Full Text] [Related]
9. Bib Pharma Monopoly: Why Consumers Keep Landing on "Park Place" and How the Game is Rigged. Levy MS Am Univ Law Rev; 2016; 66(1):247-303. PubMed ID: 28225582 [TBL] [Abstract][Full Text] [Related]
10. States sue generic drug makers for alleged price fixing. McCarthy M BMJ; 2016 Dec; 355():i6764. PubMed ID: 27993771 [No Abstract] [Full Text] [Related]
11. Balancing innovation, access, and profits--market exclusivity for biologics. Engelberg AB; Kesselheim AS; Avorn J N Engl J Med; 2009 Nov; 361(20):1917-9. PubMed ID: 19828525 [No Abstract] [Full Text] [Related]
12. Pharmaceuticals and medical devices: cost savings. ; Steiner DJ Issue Brief Health Policy Track Serv; 2012 Jan; ():1-37. PubMed ID: 22403843 [No Abstract] [Full Text] [Related]
13. The FTC v. Actavis roadmap: a guide to properly applying the rule of reason standard in reverse payment cases. Sharkey N J Leg Med; 2014; 35(3):445-66. PubMed ID: 25207633 [No Abstract] [Full Text] [Related]
14. Brazil and USA at loggerheads over production of generic antiretrovirals. Ahmad K Lancet; 2001 Feb; 357(9254):453. PubMed ID: 11273079 [No Abstract] [Full Text] [Related]
15. The "reverse payment paradox": an overview of the legality of reverse exclusionary payments in the pharmaceutical industry. Brockmeier MS Health Care Law Mon; 2010 Mar; 2010(3):2-10. PubMed ID: 20329564 [No Abstract] [Full Text] [Related]
16. The Burden of Federalism: Challenges to State Attempts at Controlling Prescription Drug Costs. Gudiksen KL; King JS J Leg Med; 2019; 39(2):95-120. PubMed ID: 31503534 [No Abstract] [Full Text] [Related]
17. A precarious balancing act--the role of the FDA as protector of public health and industry wealth. McCabe AR Suffolk Univ Law Rev; 2003; 36(3):787-819. PubMed ID: 16493844 [No Abstract] [Full Text] [Related]
18. Generics still unable to resolve ANDA patent issues by declaratory judgment, but is a supreme court resolution on the way? Eccleston LE Health Care Law Mon; 2006 Dec; ():3-5. PubMed ID: 17236678 [No Abstract] [Full Text] [Related]
19. The ongoing regulation of generic drugs. Frank RG N Engl J Med; 2007 Nov; 357(20):1993-6. PubMed ID: 18003956 [No Abstract] [Full Text] [Related]
20. Old drugs, new uses: solving a Hatch-Waxman patent predicament. McPhie DC Food Drug Law J; 2004; 59(1):155-68. PubMed ID: 15190929 [No Abstract] [Full Text] [Related] [Next] [New Search]